Certara, Inc. - Common Stock (CERT)

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

New capabilities unify Certara's biosimulation software, products, datasets, and scientific expertise with AI-driven agents to deliver specialized insights for life sciences

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Certara (CERT) To Contact Him Directly To Discuss Their Options

Reaffirms 2026 Guidance

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

LOS ANGELES, May 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Certara, Inc. (“Certara” or “the Company”) (NASDAQ: CERT) for violations of the securities laws.

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Certara (CERT) To Contact Him Directly To Discuss Their Options

The law firm of Kirby McInerney LLP is investigating potential claims against Certara, Inc. (“Certara” or the “Company”) (NASDAQ:CERT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business

Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs.

Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence 

RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money. 

RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth)